# EDGAR Filing Document

**Accession Number:** 0001022899
**File Stem:** 0001493152-26-031235
**Filing Date:** 2026-6
**Character Count:** 8770
**Document Hash:** befdf62b387f2fde904bcad2a055ffc8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-031235.hdr.sgml**: 20260630

**ACCESSION NUMBER**: 0001493152-26-031235

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260630

**DATE AS OF CHANGE**: 20260630

**EFFECTIVENESS DATE**: 20260630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Protagenic Therapeutics, Inc.\new
- **CENTRAL INDEX KEY:** 0001022899
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 061390025
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12555
- **FILM NUMBER:** 261138882

**BUSINESS ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 994-8200

**MAIL ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Atrinsic, Inc.
- **DATE OF NAME CHANGE:** 20090630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEW MOTION, INC.
- **DATE OF NAME CHANGE:** 20070504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MPLC, Inc.
- **DATE OF NAME CHANGE:** 20050608

---

| | |
|:---|:---|
| **UNITED STATES** | OMB APPROVAL |
| **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549** | OMB Number: 3235-0058<br> Expires: September 30, 2028<br> Estimated average burden |
|  | hours per response ... 2.50 |
| **FORM 12b-25** | SEC FILE NUMBER<br> 001-12555 |
| **NOTIFICATION OF LATE FILING** | CUSIP NUMBER |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(Check one):* | ☒ Form 10-K | ☐ Form 20-F | ☐ Form 11-K |  |
|  | ☐ Form 10-Q | ☐ Form 10-D | ☐ Form N-CEN | ☐ Form N-CSR |
|  | For Period Ended: | <u>March 31, 2026</u> | <u>March 31, 2026</u> |  |

---

---

| | |
|:---|:---|
| ☐ | Transition Report on Form 10-K |
| ☐ | Transition Report on Form 20-F |
| ☐ | Transition Report on Form 11-K |
| ☐ | Transition Report on Form 10-Q |
| For the Transition Period Ended: _____________________________ | For the Transition Period Ended: _____________________________ |

---

---

| |
|:---|
| *Read Instruction (on back page) Before Preparing Form. Please Print or Type.* |
| &nbsp;&nbsp;**Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.** |

---

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

---

| |
|:---|
| **Protagenic Therapeutics, Inc.** |
| Full Name of Registrant |

---

<u>N/A</u> <br> Former Name if Applicable

<u>149 Fifth Avenue</u> <br> Address of Principal Executive Office (Street and Number)

<u>New York, New York 10010</u> <br> City, State and Zip Code

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;

☒ (b) The
 subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
 thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
 or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
 fifth calendar day following the prescribed due date; and

(c) The
 accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra Sheets if Needed)

The Company has been unable to complete its Annual Report on Form 10-K within the prescribed time period without unreasonable effort or expense because additional time is required to complete the audit of its consolidated financial statements and related disclosures.

During the fiscal year, the Company entered into a business combination transaction requiring the application of complex accounting guidance, accounting, and related financial reporting considerations. Management and the Company's independent registered public accounting firm require additional time to complete their evaluation of these matters, finalize the Company's financial statements, complete required audit procedures, and complete the review of the related disclosures.

The Company currently expects to file its Annual Report on Form 10-K within the fifteen-calendar-day extension period permitted under Rule 12b-25.

**Forward-Looking Statements**

This Notification of Late Filing on Form 12b-25 contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the Company's expectation that it will complete its audit and file its Annual Report on Form 10-K within the extension period prescribed by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results or the timing of events to differ materially from those expressed or implied by such statements.

Factors that could cause actual results to differ materially include, among others, the time required to complete remaining audit procedures, the resolution of complex accounting and financial reporting matters, the completion of management's financial reporting processes, the completion of the independent registered public accounting firm's audit procedures, and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this Notification. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

**PART IV — OTHER INFORMATION**

(1) Name and telephone number
 of person to contact in regard to this notification

<u>Garo H. Armen, PhD, Principal Executive Officer and Principal Financial Officer</u> <u>212</u> <u>994-8200</u> <br> (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports
 required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
 the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is
 no, identify report(s). ☒ Yes ☐ No

(3) Is it anticipated that any
 significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings
 statements to be included in the subject report or portion thereof? ☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Protagenic Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | June 30, 2026 | By: | */s/ Garo H. Armen, PhD.,* |
|  |  |  | Principal Executive Officer and |
|  |  |  | Principal Financial Officer |

---

INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the Form.

---

| | |
|:---|:---|
| | ATTENTION |
|  | ATTENTION |
| **Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).** | **Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).** |

---